Company: Silence Therapeutics (SLN)
Date: 11th November 2020
Time: 5pm – 6pm
Presenter: Mark Rothera, President and CEO
Company Information: Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence is currently focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron overload disorders, and complement-mediated disorders.
This is a 3 step process:
1) Log in to your ShareSoc account or Join ShareSoc for free
2) Click ‘Submit’ on the form below
3) Click on the link on the next page to register with GoToWebinar to COMPLETE THE REGISTRATION
Once you have registered fully with GoToWebinar you will receive an email notification, as well as reminders 1 day and 1 hour before the event starts.